1 / 7

HL7 ICSR DSTU Update

HL7 ICSR DSTU Update. FDA progress since last working group meeting: Completed mapping to all FDA AE programs, data collection forms and E2B Completed Phase I identification of vocabulary domain requirements Completed Phase I discussions with testing partners

sai
Download Presentation

HL7 ICSR DSTU Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HL7 ICSR DSTU Update • FDA progress since last working group meeting: • Completed mapping to all FDA AE programs, data collection forms and E2B • Completed Phase I identification of vocabulary domain requirements • Completed Phase I discussions with testing partners • Completed DSTU posting of ICSR content to PSSIG website • Completed Phase I development of an “alpha-version” XFORM

  2. HL7 ICSR DSTU Update • FDA AE data element mappings: • 3500, 3500A and E2B • Harmonization with CDISC HL7 project • Harmonization with proposed next release of SPL: device identification, serial and lot numbers & other improvements

  3. HL7 ICSR DSTU Update • Phase I vocabulary requirements: • Review of ICSR Release 1 vocabulary in NCI (devices only) & identified gaps • Characterized vocabulary requirements by level of complexity: low, medium, high • Low: race/ethnicity, sex/gender, case seriousness • Medium: Actions taken, codes for distinguishing report types: primary & secondary case notifications • High: Product identification and characteristics, observations: patient, lab, concurrent observations, ICSR investigation types: AE, product problems, product evaluations

  4. HL7 ICSR DSTU Update • Discussions with testing partners: • VA reporting from VA medical centers • 3500-E2B transform for auto-load into AERS • ViSTA EMR auto-generation of ICSR • Pfizer/Brigham and Women’s Hospital: • Phase I: ODM-to-E2B transform & validation • Phase 2: ODM-to-HL7 ICSR transform • Brigham EMR auto-generation of ICSR • Mirixa Corporation (Pharmacy Services) • 3500-E2B transform for auto-load into AERS

  5. HL7 ICSR DSTU Update • DSTU Posting to HL7 and wiki site: • Needs more work – current file is still too large • Posted to PSSIG site instead of HL7 DSTU site • Created PSSIG page on wiki, but needs more work • Need to define “rules of engagement” for posting test materials, changes, progress notes • Coordinating work with ICTC

  6. HL7 ICSR DSTU Update • XFORM Development: • Completed “alpha” version for release to testing partners: Formal posting date: Oct 8th • Phase I will save as an HL7 ICSR or E2B message • Primarily text based, and next release will focus more on coding data elements

  7. NEXT STEPS • Next Steps: • Begin building test files with partners • Continue vocabulary and data element finalization • Begin Phase 2 planning for testing with new FDA AE reporting portal • Begin alignment of device ICSR R1 with R2 testing • Begin discussions with other interested partners: VICH, GHTF, ISO TC 215

More Related